|

Anhydroglucitol in Children With Type 1 Diabetes

RECRUITINGSponsored by University Hospital, Geneva
Actively Recruiting
SponsorUniversity Hospital, Geneva
Started2023-01-27
Est. completion2026-12-31
Eligibility
Age2 Years – 18 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05594706

Summary

The investigators will measure blood levels of 1,5-anhydroglucitol in children with type 1 diabetes and correlate them with parameters related to functional beta-cell mass in diabetic patients. The values will be compared to those obtained in healthy volunteers. Children with newly diagnosed diabetes as well as children with longstanding disease will be included. The aim of the study is to test the validity of 1,5-anhydroglucitol as a novel biomarker of beta-cell mass and function in type 1 diabetes.

Eligibility

Age: 2 Years – 18 YearsHealthy volunteers accepted
Inclusion Criteria:

* Type 1 diabetes with positive autoantibodies against islets, insulin, islet antigen 2 (IA2), glutamic acid decarboxylase (GAD) 65 or zinc transporter (ZnT)8.
* Treatment with continuous subcutaneous insulin infusion (CSII) with or without automated insulin delivery (AID).
* Monitoring with a continuous glucose measurement system (CGMS) or flash glucose monitor (FGM).
* Patient willing to keep the same type of CGMS or FGM during the year of observation
* Ability to give informed consent as documented by signature

Exclusion Criteria:

* Patients treated with multiple daily injections (MDI) or not willing to wear a CGMS of FGM
* Patients changing the type of CGMS during the course of the study.

Conditions2

DiabetesDiabetes Mellitus, Type 1

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.